4EGI-1

  • CAT Number: I003126
  • CAS Number: 315706-13-9
  • Molecular Formula: C18H12Cl2N4O4S
  • Molecular Weight: 451.3
  • Purity: ≥95%
Inquiry Now

4EGI-1(CAT: I003126) is a small molecule inhibitor that specifically targets eIF4E/eIF4G interaction, disrupting the eukaryotic translation initiation complex. It inhibits the binding of eIF4E to eIF4G, preventing the assembly of the translation initiation complex and subsequently inhibiting protein synthesis. 4EGI-1 has been shown to selectively inhibit the translation of oncogenic mRNAs, leading to the suppression of tumor growth in various cancer cell lines and xenograft models. Additionally, 4EGI-1 has demonstrated anti-inflammatory effects by inhibiting the synthesis of pro-inflammatory cytokines. It has potential as a therapeutic agent for cancer and inflammatory diseases.

Catalog Number I003126
CAS Number 315706-13-9
Molecular Formula

C18H12Cl2N4O4S

Purity 95%
Target eIF4E/eIF4G
Solubility DMSO: ≥ 35 mg/mL
Storage -20°C
IC50 50μM (72h, for HNE1 cell)
InChIKey KFRKRECSIYXARE-HYARGMPZSA-N
SMILES ClC1=C(Cl)C=CC(C2=CSC(N/N=C(CC3=C([N+]([O-])=O)C=CC=C3)/C(O)=O)=N2)=C1
Reference

1: Wang W, Li J, Wen Q, Luo J, Chu S, Chen L, Qing Z, Xie G, Xu L, Alnemah MM, Li
M, Fan S, Zhang H. 4EGI-1 induces apoptosis and enhances radiotherapy sensitivity
in nasopharyngeal carcinoma cells via DR5 induction on 4E-BP1 dephosphorylation.
Oncotarget. 2016 Apr 19;7(16):21728-41. doi: 10.18632/oncotarget.7824. PubMed
PMID: 26942880; PubMed Central PMCID: PMC5008318.</br>

2: Wang H, Huang F, Wang J, Wang P, Lv W, Hong L, Li S, Zhou J. The synergistic
inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and
MK2206. Cell Cycle. 2015;14(2):232-42. doi: 10.4161/15384101.2014.977096. PubMed
PMID: 25607647; PubMed Central PMCID: PMC4614875.</br>
3: Yang X, Dong QF, Li LW, Huo JL, Li PQ, Fei Z, Zhen HN. The cap-translation
inhibitor 4EGI-1 induces mitochondrial dysfunction via regulation of
mitochondrial dynamic proteins in human glioma U251 cells. Neurochem Int. 2015
Nov;90:98-106. doi: 10.1016/j.neuint.2015.07.019. Epub 2015 Jul 26. PubMed PMID:
26220902.</br>
4: Sekiyama N, Arthanari H, Papadopoulos E, Rodriguez-Mias RA, Wagner G,
Léger-Abraham M. Molecular mechanism of the dual activity of 4EGI-1: Dissociating
eIF4G from eIF4E but stabilizing the binding of unphosphorylated 4E-BP1. Proc
Natl Acad Sci U S A. 2015 Jul 28;112(30):E4036-45. doi: 10.1073/pnas.1512118112.
Epub 2015 Jul 13. PubMed PMID: 26170285; PubMed Central PMCID: PMC4522750.</br>
5: Takrouri K, Chen T, Papadopoulos E, Sahoo R, Kabha E, Chen H, Cantel S, Wagner
G, Halperin JA, Aktas BH, Chorev M. Structure-activity relationship study of
4EGI-1, small molecule eIF4E/eIF4G protein-protein interaction inhibitors. Eur J
Med Chem. 2014 Apr 22;77:361-77. doi: 10.1016/j.ejmech.2014.03.034. Epub 2014 Mar
13. PubMed PMID: 24675136; PubMed Central PMCID: PMC4128255</br>

6: Yefidoff-Freedman R, Chen T, Sahoo R, Chen L, Wagner G, Halperin JA, Aktas BH,
Chorev M. 3-substituted indazoles as configurationally locked 4EGI-1 mimetics and
inhibitors of the eIF4E/eIF4G interaction. Chembiochem. 2014 Mar 3;15(4):595-611.
doi: 10.1002/cbic.201300723. Epub 2014 Jan 23. PubMed PMID: 24458973; PubMed
Central PMCID: PMC4259117.
</br>
7: Yi T, Kabha E, Papadopoulos E, Wagner G. 4EGI-1 targets breast cancer stem
cells by selective inhibition of translation that persists in CSC maintenance,
proliferation and metastasis. Oncotarget. 2014 Aug 15;5(15):6028-37. PubMed PMID:
25115391; PubMed Central PMCID: PMC4171610.</br>
8: Papadopoulos E, Jenni S, Kabha E, Takrouri KJ, Yi T, Salvi N, Luna RE,
Gavathiotis E, Mahalingam P, Arthanari H, Rodriguez-Mias R, Yefidoff-Freedman R,
Aktas BH, Chorev M, Halperin JA, Wagner G. Structure of the eukaryotic
translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric
mechanism for dissociating eIF4G. Proc Natl Acad Sci U S A. 2014 Aug
5;111(31):E3187-95. doi: 10.1073/pnas.1410250111. Epub 2014 Jul 21. PubMed PMID:
25049413; PubMed Central PMCID: PMC4128100.</br>
9: Mahalingam P, Takrouri K, Chen T, Sahoo R, Papadopoulos E, Chen L, Wagner G,
Aktas BH, Halperin JA, Chorev M. Synthesis of rigidified eIF4E/eIF4G inhibitor-1
(4EGI-1) mimetic and their in vitro characterization as inhibitors of
protein-protein interaction. J Med Chem. 2014 Jun 26;57(12):5094-111. doi:
10.1021/jm401733v. Epub 2014 Jun 4. PubMed PMID: 24827861; PubMed Central PMCID:
PMC4216204.

Request a Quote

Contact Us at MuseChem

We are committed to providing you with reliable, cost-effective solutions for your chemical needs, while ensuring your safety and comfort. Our team of experts is always available to answer your questions and help you navigate the complexities of the chemical industry.

Whether you're looking for a specific product or need help with a custom synthesis project, we're here to help you discover a new world of chemical possibilities. Contact us today to learn more about how we can assist you with all of your chemical needs.

Our goal is to make the process of ordering chemicals as seamless and hassle-free as possible. Let us know how we can assist you, and we'll get back to you as soon as possible. We look forward to hearing from you!